Document is current
Any future updates will be listed below
-
Authors
Scafidi, Andrea
Kaoma, Tony
Cerella, Claudia
Campus, Eleonora
Grzyb, Kamil
Nosirov, Bakhtiyor
Lind-Holm Mogensen, Frida
Klein, Eliane
Da Costa, Raul
Skupin, Alexander
Hertel, Frank
Berchem, Guy
Mittelbronn, Michel
Cosma, Antonio
Melin, Beatrice
Niclou, Simone P.
Nazarov, Petr V.
Golebiewska, Anna
Poli, Aurélie
Michelucci, Alessandro https://orcid.org/0000-0003-1230-061X
-
Funding
Funding for this research was provided by:
Fonds National de la Recherche Luxembourg (PRIDE21/16763386/CANBIO2)
Fonds National de la Recherche Luxembourg (C21/BM/15739125/DIOMEDES)
Fonds National de la Recherche Luxembourg (PRIDE/14254520/I2TRON)
Fonds National de la Recherche Luxembourg (INTER/DFG/17/11583046)
Fonds National de la Recherche Luxembourg (P16/BM/11192868)
Fonds National de la Recherche Luxembourg (C24/BM/18858278/GRALL)
Fonds De La Recherche Scientifique - FNRS (7.8513.18/7651720F)
- License Information
-
More Information
Article History
Received: 7 April 2026
Accepted: 9 July 2026
First Online: 16 July 2026
Declarations
Ethics approval and consent to participate: The collection of blood and tumor tissue from glioblastoma patients is a procedure routinely carried out in the framework of a collaboration between the Neurosurgery Centre at the Centre Hospitalier de Luxembourg (CHL) and the NORLUX Neuro-Oncology Laboratory at the Luxembourg Institute of Health (LIH) ( ). All patients received a detailed information sheet and signed an informed consent form to agree to provide blood and tissue for research. The procedure was approved by the National Ethics Committee for Research (CNER, PRECISION-PDX, AVIS 201201/06), and the data collection including clinical and genetic data was authorized under pseudo-anonymized format and supervised by the National Data Protection Committee (CNPD, 929/2017) in Luxembourg. The CNER also approved the collection of blood samples from healthy donors (HEALTHY BLOOD, AVIS 202202/02).
Consent for publication: Not applicable.
Competing interests: Priority patent application filed on predictive and diagnostic biomarkers for glioma/glioblastoma (patent applicant: Luxembourg Institute of Health; inventors: AM, AnS, AP and BM). All other authors declare that they have no competing interests.
